Anil Bajnath, MD

04/16/2026

Why are younger adults getting cancer at rising rates — and what can we do about it?

A 2026 perspective published in Cell by researchers from Washington University, Yale, and the WHO's International Agency for Research on Cancer confronts one of the most urgent trends in modern oncology: the global rise of early-onset cancers in adults under 50, with particularly strong birth-cohort effects in Generation X and Millennials.

The authors argue that our current frameworks for identifying cancer causes are inadequate for this challenge. Most epidemiologic cohorts begin in midlife, health records rarely capture childhood exposures, and emerging factors like circadian disruption, ultra-processed foods, and environmental chemicals are seldom measured longitudinally. As a result, the first decades of life — precisely when many cancer-promoting biological imprints are laid down — remain largely invisible to researchers.

Their proposed solution is a shift toward tissue ecosystem-level thinking: understanding how cumulative exposures across the life course leave durable epigenetic, immune, metabolic, and microbial signatures that shape cancer susceptibility long before a diagnosis is ever made. They also call for dynamic, biology-informed risk models that update over time, and prevention frameworks anchored in cancer's natural history rather than static population averages.

This is a foundational paper for anyone thinking seriously about the future of cancer prevention.

https://doi.org/10.1016/j.cell.2026.03.019

04/15/2026

What if the reason cancer therapies fail isn't resistance — but the wrong metabolic target, in the wrong tumor, at the wrong time?

A 2025 review in Cell Reports from Yale School of Medicine examines how amino acid metabolism in cancer is not uniform — it varies between tumor types, between patients, and even between regions within the same tumor. The authors systematically cover glutamine, asparagine, aspartate, serine, methionine, cysteine, arginine, BCAAs, tyrosine, and tryptophan, demonstrating that each pathway is shaped by tissue of origin, oncogenic drivers, and the tumor microenvironment.

One striking finding: inhibiting glutaminase systemically can actually harm anti-tumor immunity by starving CD8+ T cells of glutamate — the opposite of the intended effect. Meanwhile, broader glutamine blockade enhanced immunotherapy response in lung cancer and brain tumors.

This review makes a compelling case for metabolic precision medicine — profiling the specific amino acid dependencies of a patient's tumor before selecting a therapeutic strategy.
Worth reading for any clinician or researcher working at the intersection of oncology and metabolism.

https://doi.org/10.1016/j.celrep.2025.115529

04/14/2026

What if the conditions surrounding your child's birth shaped their brain development — at the level of their DNA?

A 2026 longitudinal study from The Chinese University of Hong Kong followed 969 families from pregnancy through age 3, analyzing cord blood epigenomes and serial gut microbiome samples. Researchers found that Caesarean delivery was associated with widespread hypermethylation of genes governing neural development and neurotransmission.

Children with higher methylation of these genes had elevated ASD and ADHD scores by age 3.

What's remarkable: specific early-life gut bacteria — Lachnospira pectinoschiza and Parabacteroides distasonis — partially mitigated these epigenetic risks, mediating roughly 8% of the effect on neurodevelopmental scores.

This is among the first studies to map the epigenome-microbiome-neurodevelopment axis in humans, longitudinally, at scale. The findings point toward early microbial intervention as a plausible strategy for neurodevelopmental risk reduction.

Worth reading in full.
https://doi.org/10.1016/j.cpblue.2026.100009

04/13/2026

Why do cells lose their identity as we age? And why do the same anti-ageing interventions — partial reprogramming, chemical cocktails, chromatin-modifying therapies — consistently work across different tissues and disease contexts?

A landmark 2026 review from Harvard Medical School published in Nature Reviews Molecular Cell Biology provides the most mechanistically integrated answer to date.

Ageing, the authors argue, is not simply a random accumulation of epigenetic errors. It is a systems-level failure of chromatin's capacity to maintain cell identity — driven by four interconnected processes: the breakdown of genome architecture, the collapse of Polycomb-mediated regulatory memory, the progressive replacement of canonical histones by the variant H3.3, and the hostile takeover of gene regulatory elements by the stress-responsive transcription factor AP-1.

What makes this framework clinically important is its therapeutic clarity. The same chromatin circuit that fails during ageing can be restabilized — and cyclic expression of a single transcription factor, FOXM1, has already extended mouse median lifespan by 29% by repressing AP-1 activity and restoring youthful chromatin profiles.

For physicians and researchers in precision and functional medicine, this review maps the molecular architecture of ageing at a resolution that makes rational therapeutic design possible — not someday, but now.

📄 https://doi.org/10.1038/s41580-026-00958-0
Yücel & Gladyshev, Nature Reviews Molecular Cell Biology, March 2026

04/10/2026

One in eight Americans has now used a GLP-1 medication. Yet response varies enormously — some patients lose 25% of their body weight, others lose less than 5%. A landmark 2026 study published in Nature now explains part of why: your genes.

Researchers at 23andMe analyzed genomic data from nearly 28,000 GLP-1 medication users and identified specific variants in the receptor genes that these drugs target. A variant in GLP1R predicts meaningfully greater weight loss. A separate variant in GIPR — specific to tirzepatide users — dramatically increases the risk of vomiting, with the highest-risk patients carrying a nearly 15-fold increased likelihood of experiencing this side effect.

The study also finds that nausea and vomiting are not simply unwanted complications — they appear to share a common genetic basis with efficacy, suggesting that some of the discomfort patients experience may be biologically linked to the drug's mechanism of action.

For physicians practicing precision and functional medicine, this study provides a concrete, evidence-based foundation for genotype-guided drug selection and dose escalation in GLP-1 therapy — potentially improving outcomes and reducing unnecessary side effects from the outset of treatment.

📄 https://doi.org/10.1038/s41586-026-10330-z

Su, Ashenhurst, Auton et al., Nature, April 2026

04/08/2026

We have long known that environment shapes health. This 2026 study in Nature Medicine now quantifies precisely how much it shapes brain aging — and the answer is more substantial than most clinical frameworks currently account for.

Across 18,701 participants from 34 countries, researchers mapped 73 physical and social exposomal factors — including air pollution, access to green space, extreme precipitation, poverty, political instability, and gender inequality — against multimodal brain age clocks. The combined exposome explained up to 15.5 times more variance in brain aging than any single factor. Exposome burden increased the risk of accelerated brain aging by 3.3 to 9.1 times — surpassing the risk attributed to clinical diagnoses including Alzheimer's disease.

For physicians and researchers working in precision and functional medicine, this is a critical signal: addressing brain aging requires moving beyond pharmaceuticals and diagnostics toward the structural environmental and sociopolitical determinants that drive biological aging at scale.

📄 https://doi.org/10.1038/s41591-026-04302-z

Legaz, Moguilner, Ibanez et al., Nature Medicine, 2026

04/07/2026

One of the most underappreciated questions in cancer therapy: what happens to tumor cells that don't die after treatment?
A rigorous 2026 review from Memorial Sloan Kettering Cancer Center published in Cell addresses this directly. Many tumor cells exposed to chemotherapy, radiation, or CDK4/6 inhibitors enter a state called therapy-induced senescence — a durable growth arrest that, paradoxically, also activates potent survival programs including BCL-2 family anti-apoptotic proteins.

This creates a defined therapeutic window. Senescent tumor cells are selectively vulnerable to a class of agents called senolytics. But the window is finite — and sequential administration after senescence induction, not concurrent delivery, is what the mechanistic evidence supports.

For clinicians and researchers in precision medicine, this review provides a comprehensive, evidence-based framework for understanding senescence not as a treatment side effect, but as a programmable biological state that can be deliberately exploited.

📄 https://doi.org/10.1016/j.cell.2026.03.005
Hinterleitner et al., Cell, April 2026

04/06/2026

A rigorous 2025 review from the National Cancer Institute reframes how we should think about cancer therapy resistance.

The DNA-damage response and tumor metabolism have long been studied as distinct cancer hallmarks. This paper demonstrates they are mechanistically inseparable.

Metabolic intermediates derived from glycolysis and the TCA cycle directly modify DNA-repair proteins through post-translational mechanisms — governing homologous recombination efficiency, redox homeostasis, and the tumor cell's capacity to withstand genotoxic therapy.

For clinicians and researchers working at the intersection of oncology and precision medicine, this review provides a compelling and evidence-based rationale for combination therapeutic strategies that simultaneously target DNA repair and metabolic vulnerabilities.

The biology is detailed. The clinical implications are real. The full paper is worth your time.

📄 https://pubmed.ncbi.nlm.nih.gov/40208791/

03/30/2026

Most discussions about physical fitness focus on individual markers—VO₂ max, lab values, or specific measurements.

This study suggests that may be the wrong approach.

Researchers found that very few individual molecular markers strongly correlated with performance. Instead, what consistently explained higher fitness were coordinated biological pathways, including complement/coagulation and arginine metabolism.

This shifts the conversation. It suggests that fitness is not defined by a single measurement, but by how multiple biological systems work together.

It also highlights a broader point in medicine: complex human traits are better understood at the systems level than through isolated variables.



Reference:
https://doi.org/10.1038/s42003-026-09663-2

03/24/2026

What if cancer behaves more like a neural network than a simple mass of cells?

This review highlights a striking shift in our understanding: tumors actively interact with the nervous system. Cancer cells can form synapse-like connections with neurons, respond to neurotransmitters, and even use electrical signaling to promote growth and spread.

This has real implications. It suggests that factors like stress, neural activity, and even certain medications could influence cancer progression. It also opens the door to new treatments—targeting neural signaling alongside traditional therapies like chemotherapy and immunotherapy.

We may be entering an era where treating cancer means addressing not just the tumor, but its neural environment.



Reference:
https://doi.org/10.1038/s41392-025-02364-y

03/23/2026

Medicine has traditionally focused on individual organs, such as the heart, brain, or liver. However, new research shows that these organs function as part of an interconnected system.

A recent review highlights how organs continuously communicate through hormonal signals, immune pathways, metabolites, and neural connections. These interactions help maintain normal physiological balance.

When this communication is disrupted, disease can develop across multiple systems rather than in a single organ. Examples include heart–kidney interactions, gut–brain connections, and liver–kidney syndromes.

Advances in technologies such as multiomics, imaging, and artificial intelligence are now helping researchers better understand these complex networks.

This shift suggests that future medicine may move beyond treating individual organs toward addressing the broader system of interactions that connect them.

Reference:

Organ cross-talk, also known as the organ axis or organ interaction network, plays a vital role in maintaining physiological homeostasis and responding to environmental stimuli. This review comprehensively integrates cutting-edge observations in organ communication research, with a particular focus....

03/20/2026

Cancer is often thought of as a disease driven by genetic mutations, but new research highlights another critical dimension: metabolism.

Tumor cells can reprogram how they process fats, using lipid metabolism to support their growth, survive in challenging environments, and even influence the immune system around them.

This has important implications for treatment. Scientists are now exploring ways to target these metabolic pathways, aiming to disrupt the energy supply that cancer cells depend on.

This shift opens up new possibilities—not only for developing therapies but also for understanding how broader factors, such as diet and metabolic health, may influence cancer progression.

Reference:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12383561/